Share Awards to Executive Directors

By

Regulatory News | 28 Oct, 2024

Updated : 12:57

RNS Number : 9038J
Eco Animal Health Group PLC
28 October 2024
 

28 October 2024

 

 

 

 

 

ECO Animal Health Group plc

("ECO" or the "Company")

 

Share Awards to Executive Directors


ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, announced that on 27 October 2024, nominal cost conditional share options were granted under the Company's Long Term Incentive Plan (the "LTIP") over 329,811 ordinary shares in the Company (representing approximately 0.49 percent of the Company's issued share capital) to Executive Directors listed below.

 

Name

Position

Number of Share Awards

David Hallas

Chief Executive Officer

189,531

Chris Wilks

Chief Financial Officer

140,280

 

These awards under the LTIP are subject to performance conditions being met which have been set by the Company's Remuneration Committee and relate to Total Shareholder Return ("TSR") and Research and Development ("R&D") targets. Subject to the performance conditions being met, awards will vest after the end of a three-year vesting period. Further details on the LTIP can be found in the Company's 2024 Annual Report.

-Ends-

For further information please contact:

 

ECO Animal Health Group plc

David Hallas (CEO)

Christopher Wilks (CFO)


020 8447 8899

 

Singer Capital Markets (Nominated Adviser & Joint Broker)

Phil Davies

Sam Butcher

020 7496 3000

Investec (Joint Broker)

Gary Clarence

Lydia Zychowska

020 7597 5970

 

 

Equity Development

Hannah Crowe

Matt Evans

020 7065 2692

ICR Consilium (Financial PR)

Mary-Jane Elliott

Jessica Hodgson

020 3709 5700

ecoanimalhealth@consilium-comms.com

 


About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry. 

Click here for more information: https://ecoanimalhealth.com

 

PDMR Notification - ECO LTIP Nominal Cost Conditional Share Awards

1.           

Details of the person discharging managerial responsibilities / person closely associated

a.            

Name

David Hallas

 

2.            

Reason for the notification

a.            

Position/status

Chief Executive Officer

 

b.            

Initial notification

/Amendment

 

Initial notification

3.            

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.           

Name

Eco Animal Health Group Plc

b.           

LEI

2138009XN9DJ3YP70B55

4.            

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.            

Description of the

Financial instrument, type of instrument

Identification code

Options over ordinary shares of 5p each.

 

GB0032036807 

 

b.            

Nature of the transaction

Award of nominal cost conditional share awards under the Company's LTIP.  

c.            

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

5p

189,531

      

d.            

Aggregated information

Aggregated volume

Price 

 

 

n/a

 

e.            

Date of the transaction

27 October 2024

f.            

Place of the transaction

Off Market

 

 

1.           

Details of the person discharging managerial responsibilities / person closely associated

a.            

Name

Chris Wilks

 

2.            

Reason for the notification

a.            

Position/status

Chief Financial Officer

 

b.            

Initial notification

/Amendment

 

Initial notification

3.            

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.           

Name

Eco Animal Health Group Plc

b.           

LEI

2138009XN9DJ3YP70B55

4.            

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.            

Description of the

Financial instrument, type of instrument

Identification code

Options over ordinary shares of 5p each.

 

GB0032036807 

 

b.            

Nature of the transaction

Award of nominal cost conditional share awards under the Company's LTIP.  

c.            

Price(s) and volume(s)

 

 

Price(s)

 

Volume(s)

5p

140,280

      

d.            

Aggregated information

Aggregated volume

Price 

 

 

n/a

 

e.            

Date of the transaction

27 October 2024

f.            

Place of the transaction

Off Market

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHLVLFLZBLEFBE

Last news